

# **Diagnostics-based Infection Control**

**Herman Goossens**

**Laboratory of Medical Microbiology**

**VAXINFECTIO**

**University of Antwerp**


# **Rapid Microbial Detection Technologies**

- **Antigen detection**
  - ELISA, IF, immuno-chromatography,....
- **Nucleic acid detection**
  - PCR, real-time PCR, PCR-hybridization, DNA-microarray, PCR-sequencing,...


# Agenda

- MALDI-TOF
- Whole-Genome Sequencing
- Microbiome
- Resistome
- Future


**Matrix-assisted  
laser desorption/ionization  
time-of-flight  
mass spectrometry  
(MALDI-TOF MS)**



# MALDI-TOF Procedure



# MALDI-TOF for Identification



- Mass range 2,000-15,000 Da
- 50-70% ribosomal proteins
- Obtained spectra compared with database

# MALDI-TOF for Typing


- Staphylococci
- *Streptococcus pneumoniae*
- *Acinetobacter*
- *Escherichia coli*

# Distribution of Peak Shifts of *S. aureus* and Sensitivity and Specificity of the Markers


<i>m/z</i>	ORF	Biomarker for CC	Example(s)	Sensitivity	Specificity	No. of MRSA strains tested
2,636	PSM $\alpha$ 3					
2,685	PSM $\alpha$ 3	30	Sanger 252	0.308	1.000	13
3,007	Delta-toxin (formylated)					
3,037	Delta-toxin (formylated)	1	t127 (MW2, Sanger 476)	0.250	1.000	8
3,875	SA2420.1					
3,891	SA2420.1	5, 25	ST5, ST225, ST228, USA100, Mu50, N315	0.978	0.988	92
4,511	SAR1012	30, 45, 398, ST88	Berlin, LA-MRSA, CA-MRSA, Cowan	0.983	0.990	58
4,485	SAR1012			Peaks often not observed	Peaks often not observed	
4,497	SAR1012	(72, ST80)		Peaks often not observed	Peaks often not observed	
5,032	<i>graF</i> (SAS030)					
5,002	<i>graF</i> (SAS030)	22 (t032, t608)	Barnim EMRSA15	0.750	1.000	60
5,525	SAS049					
5,507	SAS049	30	Cowan	0.846	1.000	13
5,551	SAS049	(MSSA)				
5,539	SAS049	25, 72, 12, MSSA	Reynolds			1
6,423	<i>rpmD</i> (SA2030)					
6,397	<i>rpmD</i> (SA2030)	t032	Subgroup of CC22 strains	0.167	1.000	60
6,552	SA1452					
6,592	SA1452	8	USA300, ST247, COL (ST250)	0.889	0.996	27
6,580	SA1452	130	t843	1.000	0.992	2
6,613	<i>graC</i> (SAS044)					
6,627	<i>graC</i> (SAS044)	ST88	CA-MRSA t609	1.000	0.988	2
3,825	Truncation: no signal	45	Subgroup of CC45 strains	0.438	0.987	32




# Hierarchical Clustering of *S. aureus* and *S. epidermidis* by MALDI-TOF




# Hierarchical Clustering of *S. pneumoniae* Conjunctivitis Outbreak Isolates and Nonconjunctival Bacterial Controls by MALDI-TOF



# Hierarchical Clustering of *Acinetobacter baumannii* by rep-PCR and MALDI-TOF



# MS Spectra of *E. coli* Grown on Columbia 5% Sheep Blood Agar and Drigalski Agar



Spinali et al, J Clin Microbiol 2014

# Conclusions

- **Limitations:**

- MALDI-TOF has insufficient discriminatory power for typing of strains
- Although discriminatory potential may depend on bacterial species
- Lack of clear guidelines for data interpretation
- Variation in spectra due to culture conditions, spotting techniques
- Spectra subject to variation in protein expression and post-translational modifications and regulations


- **Expectations:**

- No great future of using MS for strain typing


# MALDI-TOF for Detection of Antibiotic Resistance

- Detection of proteins:
  - Methicillin-resistant Staphylococci
- Beta-Lactam degradation:
  - Carbapenem-resistant Gram-negative bacteria

# MS Spectra of Isogenic Strains of *S. aureus* (SCCmec- and PBP2a harboring MRSA or lacking MSSA)



# Detection of Carbapenemases



NaCl

NaCl + ertapenem

IMP-2

KPC-2

VIM-1

**Loss of peaks at 476 Da, 498 Da and 521 Da**



# Carbapenem Susceptibility Profile and Time in Days for Detection of Carbapenemase-Producing Isolates by MALDI-TOF MS

Enzyme	Microorganism (no.)	MIC range (mg/L)						Isolates detected as carbapenemase producers by MALDI-TOF MS (no.)			
		Phoenix system			agar dilution			day 1 <sup>a</sup>		day 2 <sup>b</sup>	
		ETP	IPM	MEM	ETP	IPM	MEM	2 h	4 h	2 h	4 h
KPC-2	<i>K. pneumoniae</i> (15)	>4	≤1 to >8	≤1 to >8	2 to >256	1–128	1–128	13	15	15	15
KPC-2	<i>E. cloacae</i> (2)	>4	>8	>8	>256	64–128	128	2	2	2	2
SPM-1	<i>P. aeruginosa</i> (1)	—	>8	>8	64	32	16	1	1	1	1
OXA-23	<i>A. baumannii</i> (10)	—	>8	>8	32–256	8–128	8–64	0	2	9	10
OXA-72	<i>A. baumannii</i> (1)	—	>8	>8	>256	64	128	1	1	1	1

ETP, ertapenem; IPM, imipenem; MEM, meropenem.


<sup>a</sup>Day 1, direct from positive blood culture vials.

<sup>b</sup>Day 2, direct from bacterial colony.


# Agenda

- MALDI-TOF
- **Whole-Genome Sequencing**
- Microbiome
- Resistome
- Future

# Cost per Genome (Human size)



# NEXT GENERATION SEQUENCING



# Whole-Genome Sequencing

- Detection of resistance
  - *S. aureus*
  - *P. aeruginosa*
- Typing
  - *Mycobacterium tuberculosis*
  - MRSA
  - *K. pneumoniae*
  - *A. baumannii*

# WGS for *S. aureus* genetic resistance


- WGS: 992 strains collected in Brighton and Oxford
- Catalogue of known resistance genes and mutations in housekeeping genes assoc with resistance:
  - Pubmed → Genbank
  - 12 antibiotics
- Phenotypic resistance (“gold standard”)
  - VITEK, disk diffusion
  - Discrepancies: E-test

# BLINDED VALIDATION STUDY OF RESISTANCE PREDICTION FROM WGS *STAPHYLOCOCCUS AUREUS*

Derivation set of 501 and validation set of 491; here the final results of validation set after resolving discrepant results on 487 isolates

	Phenotype: resistant		Phenotype: susceptible		Error Rates	
	Genotype		Genotype		ME	VME
Antimicrobial	Susceptible	Resistant	Susceptible	Resistant	(%)	(%)
Penicillin	2	398	84	3	3.4	0.5
Methicillin	0	55	432	0	0.0	0.0
Ciprofloxacin	2	64	421	0	0.0	3.0
Erythromycin	1	80	404	2	0.5	1.2
Clindamycin	1	76	2	0	0.0	1.3
Tetracycline	0	18	467	2	0.4	0.0
Vancomycin	0	0	491	0	0.0	n/a
Fusidic acid	1	39	445	0	0.0	2.6
Trimethoprim	0	2	200	1	0.5	0.0
Gentamicin	1	2	484	0	0.0	33.3
Mupirocin	0	2	485	0	0.0	0.0
Rifampicin	0	5	482	0	0.0	0.0
Total	8	741	4397	8	0.2	1.1

# Comparison of the Phenotypic Susceptibility Profile with the Genetic Determinants that Classify *P. aeruginosa* Isolates as Susceptible or Non-Susceptible



(C)

Microbiological Susceptibility Data

		Microbiological Susceptibility Data		
		NS	S	
Sequence Data	NS	154	14	Meropenem
	S	15	199	
	NS	181	12	Levofloxacin
	S	16	179	
	NS	63	30	Amikacin
	S	42	253	



# Conclusions of WGS for Detection of Resistance

## Limitations:

- Gene may be present, but not expressed due to unidentified alterations in regulatory region
- Alternative resistance mechanisms cannot be detected
- Complex mechanisms of resistance may be difficult to detect

## Expectations:


- Cost and turnaround time will further decrease
- WGS will replace majority of phenotypic and genotypic susceptibility tests as more genetic information becomes available

# Whole-Genome Sequencing


- Detection of resistance
  - *S. aureus*
  - *P. aeruginosa*
- **Typing**
  - *Mycobacterium tuberculosis*
  - MRSA
  - *K. pneumoniae*
  - *A. baumannii*

# Putative Transmission Networks Constructed from Genotyped Data versus Whole-Genome Data of 32 Tuberculosis Patients


**A** MIRU-VNTR and Social-Network Analysis




**B** Whole-Genome Sequencing and Social-Network Analysis




# Timeline of the Neonatal ICU MRSA Outbreak and MRSA Bacteremia Cases on Other Wards




# Results of the Phylogenetic Analysis of the 10 MRSA Isolates of Sequence Type 22




# Epidemiology and Phylogeny of an Outbreak of MRSA Sequence Type 2371 at a Baby Unit



# Graph of Possible Transmission Links among Patients Infected with Carbapenem-Resistant *Klebsiella pneumoniae* during a Hospital Outbreak




# Putative Map of *K. pneumoniae* Transmission Routes during an Outbreak Based on WGS and Patient Data





# SNP-Based Phylogenetic Analysis of Carbapenem-Resistant *K. pneumoniae* ST258 Clinical Isolates



# Microscale Evolution of *A. baumannii* within the Host

TABLE 1 Comparison of mutations between LY6 and LY7 and LY6 and LY8

CP000863 (CDS) (LY6 and LY7*)	Coding region change(s)	CP000863 (CDS) (LY6 and LY8)	Coding region change(s)
ACICU_00073	ACC55385.1:c.675A>T	ACICU_00073	ACC55385.1:c.675A>T
ACICU_00087	ACC55399.1:c.87A>T	ACICU_00087	ACC55399.1:c.87A>T
ACICU_00087	ACC55399.1:c.104G>C	ACICU_00087	ACC55399.1:c.65_66delCTTAAAG
ACICU_00088	ACC55400.1:c.202A>C	ACICU_00088	ACC56178.1:c.119_120delGGTAAAG
ACICU_00219	ACC55531.1:c.236_237delGCTAACT	ACICU_00219	ACC55531.1:c.236_237delGCTAACT
ACICU_00219	ACC55531.1:c.231_232delCAATAATC	ACICU_00219	ACC55531.1:c.231_232delCAATAATC
ACICU_01053	ACC56365.1:c.288_289delTTGAAAG	ACICU_01053	ACC56365.1:c.288_289delTTGAAAG
ACICU_01053	ACC56365.1:c.291G>A	ACICU_01053	ACC56365.1:c.291G>A
ACICU_01053	ACC56365.1:c.298G>T	ACICU_01053	ACC56365.1:c.298G>T
ACICU_01053	ACC56365.1:c.303_304delAAATAAGG	ACICU_01053	ACC56365.1:c.303_304delAAATAAGG
ACICU_01053	ACC56365.1:c.315_316delTTATAATC	ACICU_01053	ACC56365.1:c.315_316delTTATAATC
ACICU_01053	ACC56365.1:c.318_319delAAATAAGG	ACICU_01053	ACC56365.1:c.318_319delAAATAAGG
ACICU_01060	ACC56372.1:c.3414G>C	ACICU_01060	ACC56372.1:c.3429_3430delTTGAAAG
ACICU_01060	ACC56372.1:c.107T>A	ACICU_01060	ACC56372.1:c.107T>A
ACICU_01061	ACC56373.1:c.367T>G		
ACICU_02165	ACC57477.1:c.5938A>C		
ACICU_02178	ACC57490.1:c.1333T>A		
ACICU_02178	ACC57490.1:c.93A>T	ACICU_02178	ACC57490.1:c.93A>T
ACICU_02180	ACC57492.1:c.181T>A		
ACICU_02180	ACC57492.1:c.172C>T		
ACICU_02215	ACC57527.1:c.145C>A	ACICU_02215	ACC57527.1:c.145C>A
ACICU_02223	ACC57535.1:c.19_20delAAATAAGG		
ACICU_02244	ACC57556.1:c.503C>G		
ACICU_02711	ACC58023.1:c.285_288delAACAAATACTTG	ACICU_02711	ACC58023.1:c.285_288delAACAAATACTTG
ACICU_02711	ACC58023.1:c.127C>T	ACICU_02711	ACC58023.1:c.127C>T
ACICU_02711	ACC58023.1:c.165A>T	ACICU_02711	ACC58023.1:c.145_147delGCTTAAAG
ACICU_02711	ACC58023.1:c.162_163delTTGAAAG	ACICU_02711	ACC58023.1:c.140_141delCTTAAATC
ACICU_02711	ACC58023.1:c.169G>A	ACICU_02711	ACC58023.1:c.206A>G
ACICU_02712	ACC58024.1:c.525_526delTTTAAAG		
ACICU_02712	ACC58024.1:c.420C>A		
ACICU_02712	ACC58024.1:c.526G>T		
ACICU_02938	ACC58250.1:c.8delAA	ACICU_02938	ACC58250.1:c.8delAA
ACICU_02945	ACC58257.1:c.201_211insC	ACICU_02945	ACC58257.1:c.201_211insC
ACICU_03412	ACC58722.1:c.897_898delTTGAAAG		
ACICU_03412	ACC58722.1:c.881C>G		
ACICU_03412	ACC58722.1:c.873A>T		
ACICU_03412	ACC58722.1:c.213_215delAACGTTT		
ACICU_03412	ACC58722.1:c.206T>A	ACICU_03437	ACC58746.1:c.388T>C
ACICU_03412	ACC58722.1:c.191G>C	ACICU_03563	ACC58872.1:c.2853T>A
ACICU_03453	ACC58762.1:c.450T>G	ACICU_03453	ACC58762.1:c.450T>G
ACICU_03575	ACC58884.1:c.132T>G	ACICU_03575	ACC58884.1:c.132T>G
ACICU_03575	ACC58884.1:c.125T>C	ACICU_03575	ACC58884.1:c.125T>C

\* The same mutations in two pairs are highlighted in bold type. CDS, coding sequence.

# Conclusions of WGS for Typing

- WGS can allow for the identification of (unexpected) modes of transmission
- WGS may distinguish between alternative transmission scenarios which may be critical for controlling the outbreak
- WGS can link to environmental isolates which may provide insight as to how and when contamination occurred
- WGS can provide insight into how bacterial populations respond to treatments and the evolution of resistance
- WGS can help to understand or predict host response

# **Expectations of WGS for Typing**


**WGS will transform healthcare epidemiology and public health provided that:**

- WGS data is validated versus current methods
- Data are provided real-time
- At affordable cost
- Solutions for processing and storage of data
- Clinically relevant information is provided
- Data Interpretation is fully automated and can be done without specialist knowledge


# Agenda

- MALDI-TOF
- Whole-Genome Sequencing
- **Microbiome**
- **Resistome**
- Future

# Gut Microbiome Predicts Bacteremia and Helps Preventing Spread of Organisms




# The Antibiotic Resistome



# Future Practice

**IN ONE STEP GENERATE THE COMPLETE DIAGNOSTIC,  
TYPING AND SURVEILLANCE INFORMATION**





# Thank You

# Single Nucleotide Variants Identified in *K. pneumoniae* Genomes from Different Patients and Body Sites

